Difference between revisions of "Sapacitabine (CS-682)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
||
| Line 13: | Line 13: | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Revision as of 18:06, 3 February 2019
Mechanism of action
Pyrimidine analogue
Preliminary results
Acute myeloid leukemia
- Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov;13(11):1096-104. Epub 2012 Oct 15. link to original article link to PMC article PubMed